LifeTech Scientific (HKSE:01302) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01302 LifeTech Scientific Corp HKSE:01302
95 GF Score
Price HK$1.39
GF Value HK$2.12
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is LifeTech Scientific FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:01302
95GF Score
LifeTech Scientific Corp HKSE:01302
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is LifeTech Scientific (HKSE:01302) Overvalued in 2026?

Based on GuruFocus' analysis, LifeTech Scientific stock appears to be undervalued. The current stock price of HK$1.39 is trading 34.4% below its estimated GF Value™ of HK$2.12. GuruFocus considers LifeTech Scientific to be Possible Value Trap.

Key valuation signals for HKSE:01302:

  • FFO:
  • GF Value™: HK$2.12 vs. price of HK$1.39 (34.4% below fair value)
  • GF Score™: 95/100 with 4 warning signs

No single metric tells the full story. See the HKSE:01302 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

LifeTech Scientific Business Description

Address No. 22, Keji 12th Road South, 14th Floor, LifeTech Scientific Building, High-tech Industrial Park, Nanshan District, Shenzhen, CHN, 518063
LifeTech Scientific Corp develops and manufactures also responsible for marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: the Structural heart diseases business, the Peripheral vascular diseases business, and the Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral Vascular Diseases business segment. Geographically, it derives a majority of its revenue from Mainland China, and it also has its presence in Europe, Asia, excluding mainland China and India, India, South America, Africa, and Others.
95GF Score

Get the complete analysis for HKSE:01302

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.39
Price
HK$2.12
GF Value